9728太阳集团-首页|welcome

On January 8, Shanghai Liangrun Biomedical Technology Co., Ltd. was awarded the title of "Specialized, Refined, and Specialized" Enterprise in Shanghai by the Shanghai Municipal Commission of Economy and Information Technology.

Cultivating "specialized, specialized, and new" SMEs and improving the quality of SMEs' development are the important issues mentioned many times in the Shanghai Municipal Government's "Thirteenth Five-Year Plan for Promoting the Development of Small and Medium-sized Enterprises" and "Three-Year Action Plan for Promoting the Integrated Development of Large and Medium-sized Enterprises". As a model of small and medium-sized enterprises in Shanghai, "specialized, refined and new" enterprises play an important role in the future development of Shanghai.

It is reported that there are about 280,000 small and medium-sized enterprises in Pudong New Area, and only 213 enterprises have been awarded the honorary title of "Specialized, Specialized and New" in Shanghai. The selection of the list needs to go through a series of comprehensive evaluations, mainly considering the strength of the enterprise from the four perspectives of specialization, refinement, specialization and novelty. Shanghai Liangrun won this honor with its excellent scientific research ability and original products.

Shanghai Liangrun was founded in Shanghai Free Trade Zone on September 9, 2013. It is a national high-tech enterprise with nearly 50 R&D, clinical transformation and production quality management teams composed of masters and doctors. Shanghai Liangrun focuses on the early screening and diagnosis of major fatal diseases such as tumors, Alzheimer's disease, type 1.5 diabetes, and critical infectious diseases. Has obtained domestic NMPA and EU CE certification) new gastrointestinal tumor marker CST4 product (trade name "Weixiaobao"), including the new lung cancer marker FXYD product in clinical stage, is preparing for clinical exosome-based Alzheimer's disease A series of innovative products such as 4 blood tests and rapid detection of antibodies, antigens and nucleic acids for the new crown.